Poster Session 09

The last rites for cystoscopy?

Location: Room Vienna, North Hall (Level 1)
Chairs: P. Black, Vancouver (CA)
R.T. Bryan, Birmingham (GB)

Aims and objectives of this session
To understand where TCC molecular diagnostics is heading. Ready for prime time or more hype than hope?

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

117 Validation of a mRNA-based urine test for bladder cancer detection in patients with hematuria
Institutes: 1Radboudumc, Dept. of Urology, Nijmegen, The Netherlands, 2University of Nebraska Medical Center, Departments of Pathology/Microbiology, Pediatrics and Orthopaedic Surgery, Omaha, United States of America, 3Sacred Heart Hospital, Molecular Laboratory, Pensacola, United States of America, 4Pathology Inc., Clinical Laboratory, Torrance, United States of America, 5Moffitt Cancer Center, Genitourinary Oncology and Oncologic Sciences, Tampa, United States of America, 6University of Texas Southwestern, Dept. of Urology, Dallas, United States of America, 7University of Michigan Hospital, Dept. of Urology, Ann Arbor, United States of America, 8G. Kenneth Jansz MPC, Private Practice, Burlington, Canada, 9University of Tübingen, Dept. of Urology, Tübingen, Germany, 10Geisinger Health System, Dept. of Urology, Danville, United States of America, 11Urological Surgeons of Long Island, PLLC, Private Practice, Garden City, United States of America, 12Regional Urology, Private Practice, Shreveport, United States of America, 13Urology of Virginia, Private Practice, Virginia Beach, United States of America, 14Kanss City Urology Care, Private Practice, Overland Park, United States of America, 15Skyline Urology, Private Practice, Torrance, United States of America, 16UroPartners, Private Practice, Melrose Park, United States of America, 17Idaho Urologic Institute, Private Practice, Meridian, United States of America, 18Virginia Urology, Private Practice, Richmond, United States of America, 19Skyline Urology, Private Practice, Sherman Oaks, United States of America, 20Five Valleys Urology, Private Practice, Missoula, United States of America, 21Adult and Pediatric Urology & Urogynecology, Private Practice, Omaha, United States of America, 22Wichita Urology Group, Private Practice, Wichita, United States of America

118 Does smoking influence the performance of urine markers in the diagnosis of urothelial carcinoma?
By: Schnürrer S., Hennenlotter J., Dockter K., Rausch S., Stenzl A., Todenhöfer T.
Institutes: Eberhard-Karls-University, Dept. of Urology, Tübingen, Germany

119 Performance characteristics of a mRNA-based urine test for the detection of bladder cancer recurrence
Institutes: Radboudumc, Dept. of Urology, Nijmegen, The Netherlands, 2University of Nebraska Medical Center, Dept. of Pathology/Microbiolog, Pediatrics and Orthopaedic Surgery, Omaha, United States of America, 3Geisinger Health System, Dept. of Urology, Danville, United States of America, 4Sacred Heart Hospital, Molecular Laboratory, Pensacola, United States of America, 5Pathology Inc., Clinical Laboratory, Torrance, United States of America, 6Moffitt Cancer Center, Genitourinary Oncology and Oncologic Sciences, Tampa, United States of America, 7University of Texas Southwestern, Dept. of Urology, Dallas, United States of America, 8University of Michigan Hospital, Dept. of Urology, Ann Arbor, United States of America, 9G. Kenneth Jansz MPC, Private Practice, Burlington, Canada, 10University of Tübingen, Dept. of Urology, Tübingen, Germany, 11Geisinger Health System, Dept. of Urology, Danville, United States of America, 12Regional Urology, Private Practice, Shreveport, United States of America, 13Urology of Virginia, Private Practice, Virginia Beach, United States of America, 14Kansas City Urology Care, Private Practice, Overland Park, United States of America, 15Skyline Urology, Private Practice, Torrance, United States of America, 16UroPartners, Private Practice, Melrose Park, United States of America, 17Idaho Urologic Institute, Private Practice, Meridian, United States of America, 18Virginia Urology, Private Practice, Richmond, United States of America, 19Skyline Urology, Private Practice, Sherman Oaks, United States of America, 20Five Valleys Urology, Private Practice, Missoula, United States of America, 21Adult and Pediatric Urology & Urogynecology, Private Practice, Omaha, United States of America, 22Wichita Urology Group, Private Practice, Wichita, United States of America
Non invasive prediction of recurrences in bladder cancer by detecting TERT promoter mutations in urine
By: Kara N.1, Descotes F.2, Decaussin Petrucci M.2, Piaton E.3, Geiguer F.2, Rodriguez-Lafrasse C.2, Terrier J.E.2, Lopez J.2, Ruffion A.1
Institutes: 1Centre Hospitalier Lyon-Sud, Dept. of Urology, Pierre-Bénite, France, 2Centre Hospitalier Lyon-Sud, Dept. of Molecular Biology and Biochemistry, Pierre-Bénite, France

Multiplex proximity extension assay of 425 candidate biomarkers in the sera of bladder cancer patients: Correlation with stage and outcome
By: Ward D.1, Gordon N.1, Abbotts B.2, James N.3, Zeegers M.4, Cheng K.K.5, Bryan R.1
Institutes: 1University of Birmingham, Institute of Cancer and Genomic Sciences, Birmingham, United Kingdom, 2University of Birmingham, Institute Of Cancer And Genomic Sciences, Birmingham, United Kingdom, 3University of Warwick, Clinical Trials Unit, Warwick, United Kingdom, 4University of Maastricht, Dept. of Complex Genetics, Birmingham, United Kingdom, 5University of Birmingham, School of Health and Population Sciences, Birmingham, United Kingdom

Non-invasive diagnosis and monitoring of bladder cancer utilizing high-throughput genome sequencing on urine sediment
Institutes: Sun Yat-Sen Memorial Hospital, Dept. of Urology, Guangzhou, China

Method of detecting bladder cancer by optical analysis of bodily fluids
By: Rabah D.
Institutes: College of Medicine, King Saud University, Dept. of Surgery, Riyadh, Saudi Arabia

Urethral wash cytology accuracy in the diagnosis of asymptomatic urethral recurrence after radical cystectomy for urothelial bladder cancer
By: Manica M.1, Naspro R.1, Pellucchi F.1, Rocchini L.1, Roscigno M.1, Chinaglia D.2, Da Pozzo L.F.1
Institutes: 1Papa Giovanni Xxiii Hospital, Dept. of Urology, Bergamo, Italy, 2Papa Giovanni Xxiii Hospital, Dept. of Pathology, Bergamo, Italy

Diagnosis and prediction of recurrent bladder cancer by urinary DNA methylation analysis: Multicenter prospective study
By: Shindo T.1, Shimizu T.1, Nishiyama N.1, Niinuma T.2, Kitajima H.2, Kai M.2, Shinkai N.1, Itoh N.3, Tanaka T.1, Suzuki H.2, Masumori N.1
Institutes: 1Sapporo Medical University School of Medicine, Dept. of Urology, Sapporo, Japan, 2Sapporo Medical University School of Medicine, Dept. of Molecular Biology, Sapporo, Japan, 3NTT East Corporation Sapporo Hospital, Dept. of Urology, Sapporo, Japan

Urine-based diagnostics of bladder tumours through volatile organic compounds: A pilot study comparing two detection systems
127

Effect of contemporary health screening not focused on bladder cancer on diagnosis of bladder urothelial carcinoma


Institutes: Samsung Medical Center, Sungkyunkwan University School of Medicine, Dept. of Urology, Seoul, South Korea

128

Molecular tumour grading and classification of non muscle invasive bladder cancer based on whole transcriptome analysis

By: Zlotta A.R. 1, Shen J. 2, Noon A. 3, Jiang H. 4, Kuk C. 1, Ni R. 5, Sukhu B. 5, Chan K. 2, Erlich A. 1, Roupret M. 6, Seisen T. 6, Comparat E. 7, Sweet J. 8, Kulkarni G.S. 9, Fleshner N.E. 9, Azad A. 5, Van Der Kwast T.H. 1, Wrana J.L. 2

Institutes: 1 Mount Sinai Hospital, Dept. of Surgery (urology), Toronto, Canada, 2 Mount Sinai Hospital, Lunenfeld-Tanenbaum Research Institute, Toronto, Canada, 3 University of Sheffield, Dept. of Urology, Sheffield, United Kingdom, 4 University Health Network, Dept. of Statistics, Toronto, Canada, 5 Mount Sinai Hospital, Dept. of Pathology and Laboratory Medicine, Toronto, Canada, 6 Groupe Hospitalier La Pitié-Salpêtrière, Université Pierre Et Marie Curie, Dept. of Urology, Paris, France, 7 Groupe Hospitalier La Pitié-Salpêtrière, Université Pierre Et Marie Curie, Dept. of Pathology, Paris, France, 8 Toronto General Hospital, University Health Network, Dept. of Pathology, Toronto, Canada, 9 Princess Margaret Cancer Centre, University Health Network, Dept. of Surgical Oncology, Urology, Toronto, Canada

129

Significance of serum n-glycan profiling as a diagnostic biomarker in urothelial carcinoma

By: Oikawa M. 1, Hatakeyama S. 1, Yoneyama T. 1, Tobisawa Y. 1, Narita T. 1, Yamamoto H. 1, Hashimoto Y. 1, Koie T. 1, Narita S. 3, Sasaki A. 4, Tsuchiya N. 5, Habuchi T. 1, Takahashi I. 6, Nakaji S. 6, Ohyama C. 1

Institutes: 1 Hirosaki University Graduate School of Medicine, Dept. of Urology, Hirosaki, Japan, 2 Hirosaki University Graduate School of Medicine, Dept. of Advanced Transplant and Regenerative Medicine, Hirosaki, Japan, 3 Akita University Graduate School of Medicine, Dept. of Urology, Akita, Japan, 4 Tsugaru General Hospital, Dept. of Urology, Tsugaru, Japan, 5 Yamagata University Graduate School of Medicine, Dept. of Urology, Yamagata, Japan, 6 Hirosaki University School of Medicine, Dept. of Social Medicine, Hirosaki, Japan

130

Concurrent bladder tumours in patients undergoing photodynamic diagnostic ureterorenoscopy: How many lesions are missed under white light?

By: Zreik A. 1, Kata S.G. 2, Ahmad S. 2, Chlosta P.L. 3, Aboumarzouk O.M. 1

Institutes: 1 Queen Elizabeth University Hospital, Dept. of Urology, Glasgow, United Kingdom, 2 Ninewells Hospital, Dept. of Urology, Dundee, United Kingdom, 3 Jagiellonian University, Dept. of Urology, Cracow, Poland

13:49 - 13:56

Last word on the last rite

P. Black, Vancouver (CA)